Microbot Medical Inc. (NASDAQ:MBOT) Receives Consensus Rating of “Hold” from Analysts

Shares of Microbot Medical Inc. (NASDAQ:MBOT) have earned an average rating of “Hold” from the five brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.75.

MBOT has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Microbot Medical in a research report on Friday, November 28th. Roth Mkm assumed coverage on Microbot Medical in a research note on Wednesday, December 3rd. They set a “buy” rating and a $5.50 price target for the company. B. Riley Financial began coverage on Microbot Medical in a research note on Tuesday. They issued a “buy” rating on the stock. Finally, Wall Street Zen cut shares of Microbot Medical from a “hold” rating to a “sell” rating in a research note on Saturday, October 25th.

Hedge Funds Weigh In On Microbot Medical

A number of hedge funds have recently made changes to their positions in the stock. Cornerstone Advisory LLC purchased a new position in shares of Microbot Medical in the 3rd quarter worth about $30,000. Zacks Investment Management purchased a new position in Microbot Medical in the 3rd quarter valued at about $33,000. Squarepoint Ops LLC acquired a new stake in Microbot Medical during the 3rd quarter valued at approximately $37,000. Foundations Investment Advisors LLC bought a new stake in shares of Microbot Medical in the third quarter worth $38,000. Finally, SLT Holdings LLC acquired a new stake in shares of Microbot Medical in the 3rd quarter valued at about $38,000. Institutional investors and hedge funds own 16.30% of the company’s stock.

Microbot Medical Stock Up 4.5%

Microbot Medical stock opened at $1.84 on Tuesday. Microbot Medical has a 52-week low of $1.25 and a 52-week high of $4.67. The firm has a market capitalization of $123.57 million, a price-to-earnings ratio of -4.09 and a beta of 1.28. The company has a fifty day simple moving average of $2.10 and a 200-day simple moving average of $2.62.

Microbot Medical (NASDAQ:MBOT) last posted its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). On average, research analysts anticipate that Microbot Medical will post -0.71 EPS for the current fiscal year.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.